The Pharmaceutical Market: Russia

Date: January 31, 2013
Pages: 97
Price:
US$ 1,295.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PAF346A9EC4EN
Leaflet:

Download PDF Leaflet

The Pharmaceutical Market: Russia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN RUSSIA

The Russian pharmaceutical market remains a powerhouse in the Emerging Europe region . The country has by far the larg est population in the region. I ts resource s -driven economic growth is funding both private and public spending on medicines and healthcare services. The country's World Trade Organisation (WTO) accession has eliminated tariff barriers and should, in the long run, drive major improvements in a problematic intellectual property environment. Bo th domestic and cross-border mergers and acquisitions (M&A) activity has picked up since the 2009 economic crisis, a result of increased incentives for local production under the government's industrial policy for the sector and the need for scale to compete , especially in the generic medicines market. We believe a critical forward step for the market will be the successful implementation of a broad-based medicines insurance programme in the next few years, following current pilot projects. If this proves successful, we would expect growth to outstrip our current five-year projection for a compound annual growth rate of 8.3% in US dollar terms during the period 2012-2017.

Headline Expenditure Projections:

Pharmaceuticals: RUB664.72bn (US$20.96bn) in 2012 to RUR728.00bn (US$22.40bn) in 2013; +9.5% in local currency terms and 6.9% in US dollar terms. Forecast is virtually unchanged from Q412.

Healthcare: RUB2,709.62 (US$85.42bn) in 2012 to RUB2928.54bn (US$90.11bn) in 2013; +8.1% in local currency terms and +5.5% in US dollar terms. Forecast is virtually unchanged from Q412.

Medical devices: RUB209.26bn (US$6.60bn) in 2012 to RUB230.58bn (US$7.09bn) in 2013; [any reason why other stats not here? +10.2 in local currency terms and +7.5 in US dollar terms.

Competitive Landscape

The Competitive Landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
EXECUTIVE SUMMARY

SWOT ANALYSIS

    Russia Pharmaceuticals And Healthcare Industry SWOT
    Russia Political SWOT
    Russia Economic SWOT
    Russia Business Environment SWOT

PHARMACEUTICAL RISK/REWARD RATINGS

    Table: CEE Pharmaceutical Risk/Reward Ratings, Q113
    Rewards
    Risks

RUSSIA – MARKET SUMMARY

REGULATORY REGIME

    Intellectual Property Environment
    Pricing Regime And Controls
    Clinical Trials

INDUSTRY TRENDS AND DEVELOPMENTS

    Industry Developments

INDUSTRY FORECAST SCENARIO

    Overall Market Forecast
    Table: Russia Pharmaceutical Sales, Historical Data And Forecasts, 2009-2017
    Key Growth Factors – Industry
    Table: Russia Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017
    Table: Russia Government Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017
    Table: Russia Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017
    Key Growth Factors – Macroeconomic
    Table: Russia - Economic Activity, 2009-2016
    Prescription Drug Market Forecast
    Table: Russia Prescription Drug Market Indicators, Historical Data And Forecasts, 2009-2017
    Generic Drug Market Forecast
    Table: Russia Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017
    OTC Medicine Market Forecast
    Table: Russia Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts, 2009-2017
    Pharmaceutical Trade Forecast
    Table: Russia Pharmaceutical Trade Data And Forecasts (RUBmn), 2009-2017
    Table: Russia Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017
    Medical Device Market Forecast
    Table: Russia Medical Device Market Indicators, Historical Data And Forecasts, 2009-2017
    Key Risks To BMI’s Forecast Scenario

COMPETITIVE LANDSCAPE

  Manufacturing Sector
  Company Activity
    Wholesale Sector
    Retail Sector

COMPANY PROFILES

    Berlin-Chemie/Menarini Pharma GmbH
    Gedeon Richter
    Krka
    Lek (Novartis/Sandoz)
    Stada AG (Stada CIS)
    Veropharm
    Pharmstandard

DEMOGRAPHIC OUTLOOK

    Table: Russia's Population By Age Group, 1990-2020 ('000)
    Table: Russia's Population By Age Group, 1990-2020 (% of total)
    Table: Russia's Key Population Ratios, 1990-2020
    Table: Russia's Rural And Urban Population, 1990-2020

GLOSSARY

BMI METHODOLOGY

    How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceuticals Risk/Reward Ratings Methodology
    Ratings Overview
    Table: Pharmaceutical Business Environment Indicators
    Weighting
    Table: Weighting Of Components
    Sources
Skip to top


Looking at Offshoring in the Pharmaceutical Industry US$ 300.00 Jun, 2011 · 50 pages
The Pharmaceutical Market: Egypt US$ 1,295.00 Jan, 2013 · 111 pages
The Pharmaceutical Market: Finland US$ 1,295.00 Mar, 2013

Ask Your Question

The Pharmaceutical Market: Russia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: